A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis Abstract

Sik Hung SUEN, Sammy Chung Sum CHAN

Objective:
To evaluate the suppression of pituitary gonadotrophins and ovarian steroid hormones with the administration of a combination of leuprorelin depot 3.75 mg and leuprorelin depot 11.25 mg at 5 weeks apart.

Design:
Prospective open observational study.

Setting:
Gynaecology department of a public hospital under Hospital Authority in Hong Kong.

Patients:
25 consecutive symptomatic patients with laparoscopy or laparotomy proven stage III and stage IV pelvic endometriosis were recruited from February 2003 to July 2004.

Main outcome measures:
Serum levels of 17-b-oestradiol, follicle-stimulating hormone and luteinising hormone; pelvic pain scores.

Other outcome measures:
Side-effects and non-responders.

Results:
This regimen of treatment was found to significantly suppress the endogenous oestradiol level to postmenopausal range and the pain scores to a very low level. These effects were well maintained till 24 weeks after commencement of treatment. Side-effects were mainly hot flushes and sweating and were tolerable by all subjects.

Conclusion:
The combination of leuprorelin 3.75 mg and leuprorelin 11.25 mg 3 Month Depot is a safe and effective alternative to conventional monthly injection of gonadotrophin-releasing hormone agonists. It can be recommended as a more cost-effective and patient-friendly alternative in the treatment of pelvic endometriosis.

Hong Kong J Gynaecol Obstet Midwifery 2005; 5:2-9

Full Text (PDF)

  Copyright © 2021 by the Obstetrical & Gynaecological Society of Hong Kong
  and the Hong Kong Midwives Association
  Print ISSN:1608-9367
  Online ISSN:2225-904X
  This website is developed and maintained by
  the HKAM Press